The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N01 | Anesthetics | |
3
|
N01A | Anesthetics, general | |
4
|
N01AX | Other general anesthetics |
| Code | Title | |
|---|---|---|
| N01AX03 | Ketamine | |
| N01AX04 | Propanidid | |
| N01AX05 | Alfaxalone | |
| N01AX07 | Etomidate | |
| N01AX10 | Propofol | |
| N01AX11 | Hydroxybutyric acid | |
| N01AX13 | Nitrous oxide | |
| N01AX14 | Esketamine | |
| N01AX15 | Xenon | |
| N01AX63 | Nitrous oxide, combinations |
| Active Ingredient |
|---|
|
Esketamine is the S-enantiomer of racemic ketamine. It is a non-selective, non-competitive, antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. Through NMDA receptor antagonism, esketamine produces a transient increase in glutamate release leading to increases in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) stimulation and subsequently to increases in neurotrophic signalling which may contribute to the restoration of synaptic function in these brain regions involved with the regulation of mood and emotional behaviour. Restoration of dopaminergic neurotransmission in brain regions involved in the reward and motivation, and decreased stimulation of brain regions involved in anhedonia, may contribute to the rapid response. |
|
Etomidate is an imidazole derivative with short-acting sedative, hypnotic, and general anesthetic properties. Etomidate appears to have gamma-aminobutyric acid (GABA) like effects, mediated through GABA-A receptor. The action enhances the inhibitory effect of GABA on the central nervous system by causing chloride channel opening events which leads to membrane hyperpolarization. |
|
Ketamine is a rapidly acting general anaesthetic for intravenous or intramuscular use with a distinct pharmacological action. Ketamine hydrochloride produces dissociative anaesthesia characterised by catalepsy, amnesia, and marked analgesia which may persist into the recovery period. |
|
Nitrous oxide is a potent analgesic and a weak anaesthetic. Induction with nitrous oxide is relatively rapid, but a concentration of about 70% is needed to produce unconsciousness. |
|
Propofol (2, 6-diisopropylphenol) is a short-acting general anaesthetic agent with a rapid onset of action of approximately 30 seconds. |
|
Sodium oxybate is a central nervous system depressant which reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy and modifies sleep architecture reducing fragmented nighttime sleep. The precise mechanism by which sodium oxybate produces an effect is unknown, however sodium oxybate is thought to act by promoting slow (delta) wave sleep and consolidating night-time sleep. |
| Document | Type | Information Source | |
|---|---|---|---|
| DIPRIVAN Emulsion for injection or infusion | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| HYPNOMIDATE Solution for injection | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| KETALAR Solution for injection or infusion | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| MILSIA Emulsion for injection/infusion | MPI, Generic | Health Products Regulatory Authority (ZA) | |
| PROPOVEN Emulsion for injection/infusion | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| PROVIVE Emulsion for injection | MPI, EU: SmPC | Medicines and Medical Devices Safety Authority (NZ) |